Alpha Emitter Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     Global Alpha Emitter 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  the  la tes t  repor t  by  IMARC Group ,  t i t l ed  "Alpha  Emit ter  Market :  
Globa l  Industry  Trends,  Share ,  S ize ,  Growth,  Opportuni ty  and Forecas t  
2024 -2032 ,"  the  g loba l  a lpha  emi t te r  marke t  s i ze  reached  US$ 1 ,476 .8  Mi l l i on  
in  2023 .
Factors Af fect ing the Growth of  the Alpha Emitter  Industry:
Report Increasing Prevalence of  Cancer:
The r is ing  p reva lence  o f  cancer  among  the  masses  ac ross  the  g lobe  is  
Highlight and ca ta lyz ing  the  demand fo r  a lpha  emi t te rs .  The  g rowing  need  fo r  advanced  t rea tment  op t ions  l i ke  ta rge ted  a lpha -par t i c le  the rapy  (TAT)  among ind iv idua ls  
who  a re  d iagnosed  w i th  va r ious  types  o f  cancer ,  espec ia l l y  those  tha t  a re  
Description aggress ive  and  d i f f i cu l t  to  t rea t  w i th  conven t iona l  t he rap ies ,  i s  o f fe r ing  a  
favorab le  marke t  ou t look .  
A lpha  emi t te rs  de l i ve r  h igh -energy  par t i c les  d i rec t l y  to  cancer  ce l l s  w i th  
min ima l  impac t  on  su r round ing  hea l thy  t i ssues ,  mak ing  them c ruc ia l  in  t he  
f i gh t  aga ins t  cance r .  Th is  ta rge ted  approach  is  pa r t i cu la r ly  e f fec t ive  fo r  
t rea t ing  metas ta t ic  cancers  and  those  tha t  have  deve loped  res is tance  to  
t rad i t i ona l  the rap ies .
Advancements in Radiopharmaceut icals:
Techno log ica l  advancemen ts  in  rad iopharmaceu t i ca ls  a re  revo lu t ion iz ing  the  
f i e ld  o f  nuc lear  med ic ine .  Innova t ions  in  the  deve lopment ,  p roduc t ion ,  and  
app l ica t ion  o f  rad iopha rmaceu t i ca ls  improve  the  e f f i cacy ,  sa fe ty ,  and  
access ib i l i t y  o f  a lpha  emi t te rs  in  med ica l  t rea tments .  These  advancemen ts  
Report i nc lude  be t te r  ta rge t ing  mechan isms ,  enhanced  imag ing  techn iques ,  and  the  
deve lopment  o f  new i so topes  tha t  p rov ide  more  e f fec t ive  t rea tment  op t ions .  
Highlight and The ab i l i t y  t o  accura te ly  de l i ve r  a lpha  emi t te rs  to  cancer  ce l l s  wh i le  min im iz ing  
damage  to  hea l thy  t i ssues  i s  mak ing  these  the rap ies  more  appea l ing  to  bo th  
hea l thcare  p rov ide rs  and  pa t ien ts .  Fu r the rmore ,  improvements  in  
Description rad iopharmaceu t ica l  p roduc t ion  p rocesses  a re  lead ing  to  inc reased  ava i lab i l i t y  
and  reduced  cos ts .
Growing Demand for  Targeted Therapy:
The sh i f t  t owards  persona l ized  and  ta rge ted  cancer  the rap ies  is  suppor t ing  the  
marke t  g rowth .  Ta rge ted  the rapy  focuses  on  spec i f i c  mo lecu les  o r  pa thways  
tha t  a re  invo lved  in  the  g rowth  and  su rv iva l  o f  cancer  ce l l s ,  o f fe r ing  a  more  
p rec ise  t rea tment  approach  as  compared  to  t rad i t i ona l  chemo therapy  o r  
rad ia t ion .
Alpha  emi t te rs  p lay  a  c ruc ia l  ro le  in  th is  the rapeu t ic  s t ra tegy  by  de l ive r ing  
po ten t  rad ia t ion  d i rec t l y  to  cancer  ce l l s ,  t he reby  reduc ing  co l la te ra l  damage to  
hea l thy  t i ssues .  Th is  p rec is ion  i s  pa r t i cu la r ly  impor tan t  f o r  t rea t ing  cance rs  
tha t  a re  d i f f i cu l t  t o  reach  o r  have  sp read  to  mu l t ip le  a reas  in  the  body .
Report Request  for  a  PDF sample  o f  th is  repor t :  h t tps : / /www. imarcgroup .com/a lpha-emi t te r -marke t / reques tsamp le
Highlight and 
Description
Report Description
Global  Alpha Emitter  Market  Trends:
Govern ing agenc ies  o f  var ious count r ies  are focusing on prov id ing funding for  advanc ing cancer  research 
and t rea tment ,  which is  impel l ing the market  growth.  These in i t ia t ives o f ten inc lude grants ,  subs id ies,  and 
par tnersh ips  that  fac i l i ta te  research and expedi te  the c l in ica l  t r ia l  process.  A lpha emi t ter  therap ies  are 
increasing ly  rece iv ing regula tory  approval  and benef i t  f rom governmenta l  back ing,  which is  bo ls ter ing  the 
market  growth.  
The therapeut ic  potent ia l  o f  a lpha emi t ters  is  su i tab le  in  o ther  areas,  such as neuro logy,  in fec t ious 
d iseases,  and card iovascular  condi t ions.  In  neuro logy,  a lpha emi t ters  are invest igated for  the i r  ab i l i ty  to  
target  and dest roy  amylo id  p laques in  A lzheimer ’s  d isease,  potent ia l ly  o f fer ing a new t reatment  avenue.  
S imi lar ly ,  in  in fec t ious d iseases,  a lpha emi t ters  can be used to  target  and e l iminate drug-res is tant  bacter ia  
or  v i ruses.
View Report  TOC,  F igures and Tables :  ht tps: / /www.imarcgroup.com/alpha-emit ter -market
Breakup by Type of Radionuclide:
• Astat ine
• Radium
• Actinium
• Lead
• Bismuth
Report • Others
Segmentation
Breakup by Medical Application:
• Prostate Cancer
• Bone Metastasis
• Ovarian Cancer
• Pancreat ic Cancer
• Endocr ine Tumors
• Others
Breakup by End User:
• Hospitals
• Medical  Research Insti tut ions
• Others
Report 
Segmentation Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
• Actinium Pharmaceuticals Inc.
• Alpha Tau Medical  Ltd.
• Bayer AG
Competitive • Fusion Pharmaceuticals
• IBA RadioPharma Solutions
Landscape 
• RadioMedix Inc.
with Key 
Players
What was the size of the global alpha emitter 
market in 2023?
What is the expected growth rate of the global 
alpha emitter market during 2024-2032?
What are the key factors driving the global alpha 
Key emitter market?
Questions What has been the impact of COVID-19 on the 
global alpha emitter market?
Answered in 
What is the breakup of the global alpha emitter 
the Report market based on the type of radionuclide?
What is the breakup of the global alpha emitter 
market based on the medical application?
What are the key regions in the global alpha 
emitter market?
Who are the key players/companies in the global 
alpha emitter market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  A l p h a  E m i t t e r  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  T y p e  o f  R a d i o n u c l i d e
    6 . 1     A s t a t i n e  
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     R a d i u m  
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     A c t i n i u m  
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
       
   6 . 4     L e a d  
        6 . 4 . 1  M a r k e t  T r e n d s
        6 . 4 . 2  M a r k e t  F o r e c a s t
    6 . 5     B i s m u t h  
        6 . 5 . 1  M a r k e t  T r e n d s
        6 . 5 . 2  M a r k e t  F o r e c a s t
    6 . 6     O t h e r s
        6 . 6 . 1  M a r k e t  T r e n d s
        6 . 6 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  M e d i c a l  A p p l i c a t i o n
Table of     7 . 1     P r o s t a t e  C a n c e r        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
Contents     7 . 2     B o n e  M e t a s t a s i s        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     O v a r i a n  C a n c e r
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     P a n c r e a t i c  C a n c e r
        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
    7 . 5     E n d o c r i n e  T u m o r s
        7 . 5 . 1  M a r k e t  T r e n d s
        7 . 5 . 2  M a r k e t  F o r e c a s t
    7 . 6     O t h e r s
        7 . 6 . 1  M a r k e t  T r e n d s
        7 . 6 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /a lph a -em i t te r-m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: